Arcus Biosciences, Inc.
Clinical trials sponsored by Arcus Biosciences, Inc., explained in plain language.
Biotech developing cancer immunotherapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug AB801 enters human safety testing Results expected Nov 2026 (estimated) May already have reported ↗
- New drug AB102 enters first human safety tests Results expected Dec 2026 (estimated) May already have reported ↗
- New hope for advanced stomach cancer: drug cocktails under trial Results expected Jan 2027 (estimated) May already have reported ↗
- Liver health and drug processing: a closer look at casdatifan Results expected May 2027 (estimated) May already have reported ↗
- Double immunotherapy attack shows promise for tough lung cancer Results expected May 2027 (estimated) May already have reported ↗
-
New combo therapy aims to slow advanced kidney cancer
Disease control Recruiting nowThis study tests whether adding the experimental drug casdatifan to the standard drug cabozantinib can slow cancer growth better than cabozantinib alone in people with advanced clear cell kidney cancer. About 720 adults whose cancer worsened after prior immunotherapy will receive…
Phase 3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat kidney cancer
Disease control Recruiting nowThis early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Liver health and drug processing: a closer look at casdatifan
Knowledge-focused Recruiting nowThis study is testing how the body processes a single dose of casdatifan, an experimental drug, in people with moderate liver impairment compared to healthy volunteers. The goal is to see if liver function changes how the drug is absorbed and cleared from the body. Participants r…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New drug AB102 enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage trial is the first to test AB102 in humans. It will give the drug to 130 healthy volunteers to check its safety and how the body processes it. The study is not designed to treat any disease, but to gather essential information for future research.
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC